Icon Plc (ICLR) 69.24 $ICLR
My Top Life Sciences Tools And Services Stocks For 2015
Stan Stafford - at Seeking Alpha - Wed Apr 22, 12:57AM CDT
PRXL: 67.12 (-0.42), Q: 66.45 (-0.25), CBM: 42.07 (-0.65), TMO: 130.69 (-3.75), NEO: 4.84 (-0.03), ILMN: 190.04 (-9.27), LMNX: 16.34 (-0.01), CRL: 78.06 (-0.53), PKI: 51.69 (-0.02), ICLR: 69.24 (+1.28), MTD: 324.14 (+0.66)
ICON Up 28.6% Since SmarTrend Uptrend Call (ICLR)
Comtex SmarTrend(R) - Tue Apr 21, 9:27AM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on January 8th, 2015 at $54.04. In approximately 3 months, ICON has returned 28.60% as of today's recent price of $69.49.
ICLR: 69.24 (+1.28)
ICON Shares Up 27.5% Since SmarTrend's Buy Recommendation (ICLR)
Comtex SmarTrend(R) - Mon Apr 13, 5:08PM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on January 8th, 2015 at $54.04. In approximately 3 months, ICON has returned 27.55% as of today's recent price of $68.92.
ICLR: 69.24 (+1.28)
Cancer Genetics (CGIX) Shows Strength: Stock Gains 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 8:25AM CDT
Cancer Genetics (CGIX) was a big mover last session, with shares rising roughly 6% on the day.
ICLR: 69.24 (+1.28), CGIX: 9.97 (-0.18)
New Book by Industry Thought Leaders Advocates for Re-Engineering Clinical Trials
Business Wire - Mon Apr 13, 6:30AM CDT
ICON plc (NASDAQ: ICLR), a global provider of drug and development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the release of the book "Re-Engineering Clinical Trials" (ISBN: 9780124202467), edited and co-authored by Brendan Buckley, ICON's Chief Medical Officer, and Peter Schuler, ICON's SVP of Global Medical and Safety Services.
IBM: 165.36 (+1.10), ICLR: 69.24 (+1.28)
MedAssets: A Strong Sell on Tepid View, Estimate Revision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 1:00PM CDT
On Apr 9, 2015, Zacks Investment Research downgraded MedAssets Inc (MDAS) to a Zacks Rank #5 (Strong Sell).
AIRM: 47.47 (+1.42), XON: 44.53 (+0.36), MDAS: 20.08 (+0.13), ICLR: 69.24 (+1.28)
Vestar Capital-backed PGA Holdings Files for $100 Million IPO
at The Street - Wed Apr 08, 9:43AM CDT
Press Ganey did not reveal Vestar's current stake or how many shares it would sell but noted the New York firm would continue to have a controlling interest.
CIVI: 19.26 (+0.01), ICLR: 69.24 (+1.28), SJM: 117.94 (+0.50)
ICON Has Returned 29.7% Since SmarTrend Recommendation (ICLR)
Comtex SmarTrend(R) - Mon Apr 06, 11:12AM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on January 8th, 2015 at $54.04. In approximately 3 months, ICON has returned 29.66% as of today's recent price of $70.06.
ICLR: 69.24 (+1.28)
Air Methods Now a Strong Buy: Is It in Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 10:00AM CDT
On Mar 27, 2015, Zacks Investment Research upgraded medical services provider Air Methods Corp (AIRM) to a Zacks Rank #1 (Strong Buy).
AIRM: 47.47 (+1.42), XON: 44.53 (+0.36), TXT: 44.71 (+0.05), ICLR: 69.24 (+1.28)
Is ICON Public Limited (ICLR) a Great Growth Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 24, 7:35AM CDT
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention and produce gains; and one such company that might be well-positioned for future earnings growth is ICON Public Limited.
ICLR: 69.24 (+1.28)
ICON and Carnegie Mellon University Collaborate to Evaluate Patient-centric Informed Consent Processes
Business Wire - Mon Mar 23, 7:00AM CDT
ICON plc, (NASDAQ:ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it is sponsoring a series of research projects, led by Professor Baruch Fischhoff, Ph.D., at Carnegie Mellon University (CMU), to find new ways to improve information comprehension and retention by clinical trial participants. The research tools will include multimedia solutions from ICON's Firecrest suite of products.
ICLR: 69.24 (+1.28)
Biogen, Five Other Top Stocks Show No Sign Of Slowing
at Investor's Business Daily - Fri Mar 20, 3:19PM CDT
Biogen Idec (BIIB) led a handful of Spotlight stocks to new highs Friday as the market rallied. Biogen blasted about 10% in huge volume after the company reported better-than-expected results for its much-anticipated treatment for Alzheimer's...
BIIB: 423.57 (+1.46), PBH: 43.16 (-1.02), SWKS: 96.83 (+1.41), ICLR: 69.24 (+1.28), AVGO: 127.89 (+4.79)
Shares of ICLR Up 32.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Mar 20, 9:27AM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on January 8th, 2015 at $54.04. In approximately 2 months, ICON has returned 32.32% as of today's recent price of $71.50.
ICLR: 69.24 (+1.28)
How ICON Public Limited (ICLR) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 7:54AM CDT
ICON Public Limited is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
ICLR: 69.24 (+1.28)
Why ICON Public Limited (ICLR) Could Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 19, 7:33AM CDT
ICON Public Limited has seen a nice streak of beating earnings estimates at the previous two reports, suggesting it has a nice short-term history of crushing expectations and that it could be a great candidate for another beat.
ICLR: 69.24 (+1.28)
Shares of ICLR Up 26.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 12, 5:04PM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on January 8th, 2015 at $54.04. In approximately 2 months, ICON has returned 26.21% as of today's recent price of $68.20.
ICLR: 69.24 (+1.28)
ICON Launches Medical Device, Diagnostics Research Group - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 4:56PM CDT
ICON Public Limited Company (ICLR) recently announced the launch of a new Medical Device & Diagnostics Research group, close on the heels of the acquisition of MediMedia Pharma Solutions and stellar fourth quarter 2014 results.
ABMD: 69.31 (-0.40), ABAX: 63.25 (-0.09), ICLR: 69.24 (+1.28), AFFX: 12.57 (-0.13)
Watch Out, There Is An M&A Transaction In Every Major CRO's Playbook For 2015-2017
Rudy Sangari - at Seeking Alpha - Thu Mar 12, 7:49AM CDT
Q: 66.45 (-0.25), LH: 126.26 (+0.35), ICLR: 69.24 (+1.28), CVD: 106.42 (-0.71)
ICON Raised to Strong Buy on Stellar Q4, Strategic Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 1:00PM CDT
On Mar 10, Zacks Investment Research upgraded ICON Public Limited Company (ICLR) to a Zacks Rank #1 (Strong Buy)
ABAX: 63.25 (-0.09), LMNX: 16.34 (-0.01), ICLR: 69.24 (+1.28), AFFX: 12.57 (-0.13)
My Top Life Sciences Tools And Services Stocks For 2015
Stan Stafford - at Seeking Alpha - Wed Apr 22, 12:57AM CDT
PRXL: 67.12 (-0.42), Q: 66.45 (-0.25), CBM: 42.07 (-0.65), TMO: 130.69 (-3.75), NEO: 4.84 (-0.03), ILMN: 190.04 (-9.27), LMNX: 16.34 (-0.01), CRL: 78.06 (-0.53), PKI: 51.69 (-0.02), ICLR: 69.24 (+1.28), MTD: 324.14 (+0.66)
ICON Up 28.6% Since SmarTrend Uptrend Call (ICLR)
Comtex SmarTrend(R) - Tue Apr 21, 9:27AM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on January 8th, 2015 at $54.04. In approximately 3 months, ICON has returned 28.60% as of today's recent price of $69.49.
ICLR: 69.24 (+1.28)
ICON Shares Up 27.5% Since SmarTrend's Buy Recommendation (ICLR)
Comtex SmarTrend(R) - Mon Apr 13, 5:08PM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on January 8th, 2015 at $54.04. In approximately 3 months, ICON has returned 27.55% as of today's recent price of $68.92.
ICLR: 69.24 (+1.28)
Cancer Genetics (CGIX) Shows Strength: Stock Gains 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 8:25AM CDT
Cancer Genetics (CGIX) was a big mover last session, with shares rising roughly 6% on the day.
ICLR: 69.24 (+1.28), CGIX: 9.97 (-0.18)
New Book by Industry Thought Leaders Advocates for Re-Engineering Clinical Trials
Business Wire - Mon Apr 13, 6:30AM CDT
ICON plc (NASDAQ: ICLR), a global provider of drug and development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the release of the book "Re-Engineering Clinical Trials" (ISBN: 9780124202467), edited and co-authored by Brendan Buckley, ICON's Chief Medical Officer, and Peter Schuler, ICON's SVP of Global Medical and Safety Services.
IBM: 165.36 (+1.10), ICLR: 69.24 (+1.28)
MedAssets: A Strong Sell on Tepid View, Estimate Revision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 1:00PM CDT
On Apr 9, 2015, Zacks Investment Research downgraded MedAssets Inc (MDAS) to a Zacks Rank #5 (Strong Sell).
AIRM: 47.47 (+1.42), XON: 44.53 (+0.36), MDAS: 20.08 (+0.13), ICLR: 69.24 (+1.28)
Vestar Capital-backed PGA Holdings Files for $100 Million IPO
at The Street - Wed Apr 08, 9:43AM CDT
Press Ganey did not reveal Vestar's current stake or how many shares it would sell but noted the New York firm would continue to have a controlling interest.
CIVI: 19.26 (+0.01), ICLR: 69.24 (+1.28), SJM: 117.94 (+0.50)
ICON Has Returned 29.7% Since SmarTrend Recommendation (ICLR)
Comtex SmarTrend(R) - Mon Apr 06, 11:12AM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on January 8th, 2015 at $54.04. In approximately 3 months, ICON has returned 29.66% as of today's recent price of $70.06.
ICLR: 69.24 (+1.28)
Air Methods Now a Strong Buy: Is It in Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 10:00AM CDT
On Mar 27, 2015, Zacks Investment Research upgraded medical services provider Air Methods Corp (AIRM) to a Zacks Rank #1 (Strong Buy).
AIRM: 47.47 (+1.42), XON: 44.53 (+0.36), TXT: 44.71 (+0.05), ICLR: 69.24 (+1.28)
Is ICON Public Limited (ICLR) a Great Growth Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 24, 7:35AM CDT
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention and produce gains; and one such company that might be well-positioned for future earnings growth is ICON Public Limited.
ICLR: 69.24 (+1.28)
ICON and Carnegie Mellon University Collaborate to Evaluate Patient-centric Informed Consent Processes
Business Wire - Mon Mar 23, 7:00AM CDT
ICON plc, (NASDAQ:ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it is sponsoring a series of research projects, led by Professor Baruch Fischhoff, Ph.D., at Carnegie Mellon University (CMU), to find new ways to improve information comprehension and retention by clinical trial participants. The research tools will include multimedia solutions from ICON's Firecrest suite of products.
ICLR: 69.24 (+1.28)
Biogen, Five Other Top Stocks Show No Sign Of Slowing
at Investor's Business Daily - Fri Mar 20, 3:19PM CDT
Biogen Idec (BIIB) led a handful of Spotlight stocks to new highs Friday as the market rallied. Biogen blasted about 10% in huge volume after the company reported better-than-expected results for its much-anticipated treatment for Alzheimer's...
BIIB: 423.57 (+1.46), PBH: 43.16 (-1.02), SWKS: 96.83 (+1.41), ICLR: 69.24 (+1.28), AVGO: 127.89 (+4.79)
Shares of ICLR Up 32.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Mar 20, 9:27AM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on January 8th, 2015 at $54.04. In approximately 2 months, ICON has returned 32.32% as of today's recent price of $71.50.
ICLR: 69.24 (+1.28)
How ICON Public Limited (ICLR) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 7:54AM CDT
ICON Public Limited is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
ICLR: 69.24 (+1.28)
Why ICON Public Limited (ICLR) Could Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 19, 7:33AM CDT
ICON Public Limited has seen a nice streak of beating earnings estimates at the previous two reports, suggesting it has a nice short-term history of crushing expectations and that it could be a great candidate for another beat.
ICLR: 69.24 (+1.28)
Shares of ICLR Up 26.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 12, 5:04PM CDT
SmarTrend identified an Uptrend for ICON (NASDAQ:ICLR) on January 8th, 2015 at $54.04. In approximately 2 months, ICON has returned 26.21% as of today's recent price of $68.20.
ICLR: 69.24 (+1.28)
ICON Launches Medical Device, Diagnostics Research Group - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 4:56PM CDT
ICON Public Limited Company (ICLR) recently announced the launch of a new Medical Device & Diagnostics Research group, close on the heels of the acquisition of MediMedia Pharma Solutions and stellar fourth quarter 2014 results.
ABMD: 69.31 (-0.40), ABAX: 63.25 (-0.09), ICLR: 69.24 (+1.28), AFFX: 12.57 (-0.13)
Watch Out, There Is An M&A Transaction In Every Major CRO's Playbook For 2015-2017
Rudy Sangari - at Seeking Alpha - Thu Mar 12, 7:49AM CDT
Q: 66.45 (-0.25), LH: 126.26 (+0.35), ICLR: 69.24 (+1.28), CVD: 106.42 (-0.71)
ICON Raised to Strong Buy on Stellar Q4, Strategic Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 1:00PM CDT
On Mar 10, Zacks Investment Research upgraded ICON Public Limited Company (ICLR) to a Zacks Rank #1 (Strong Buy)
ABAX: 63.25 (-0.09), LMNX: 16.34 (-0.01), ICLR: 69.24 (+1.28), AFFX: 12.57 (-0.13)
